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httpIntraoperative use of dextran is associated with
cardiac complications after carotid endarterectomy
Alik Farber, MD,a Tze-Woei Tan, MD,b Denis Rybin, MS,a Jeffrey A. Kalish, MD,a
Naomi M. Hamburg, MD,a Gheorghe Doros, PhD,a Philip P. Goodney, MD,c and
Jack L. Cronenwett, MD,c on behalf of the Vascular Study Group of New England, Boston, Mass; Shreveport,
La; and Lebanon, NH
Objective: Although dextran has been theorized to diminish the risk of stroke associated with carotid endarterectomy
(CEA), variation exists in its use. We evaluated outcomes of dextran use in patients undergoing CEA to clarify its utility.
Methods: We studied all primary CEAs performed by 89 surgeons within the Vascular Study Group of New England
database (2003-2010). Patients were stratiﬁed by intraoperative dextran use. Outcomes included perioperative death,
stroke, myocardial infarction (MI), and congestive heart failure (CHF). Group and propensity score matching was
performed for risk-adjusted comparisons, and multivariable logistic and gamma regressions were used to examine asso-
ciations between dextran use and outcomes.
Results: There were 6641 CEAs performed, with dextran used in 334 procedures (5%). Dextran-treated and untreated
patients were similar in age (70 years) and symptomatic status (25%). Clinical differences between the cohorts were
eliminated by statistical adjustment. In crude, group-matched, and propensity-matched analyses, the stroke/death rate
was similar for the two cohorts (1.2%). Dextran-treated patients were more likely to suffer postoperative MI (crude: 2.4%
vs 1.0%; P[ .03; group-matched: 2.4% vs 0.6%; P[ .01; propensity-matched: 2.4% vs 0.5%; P[ .003) and CHF (2.1%
vs 0.6%; P[ .01; 2.1% vs 0.5%; P[ .01; 2.1% vs 0.2%; P < .001). In multivariable analysis of the crude sample, dextran
was associated with a higher risk of postoperative MI (odds ratio, 3.52; 95% conﬁdence interval, 1.62-7.64) and CHF
(odds ratio, 5.71; 95% conﬁdence interval, 2.35-13.89).
Conclusions: Dextran use was not associated with lower perioperative stroke but was associated with higher rates of MI
and CHF. Taken together, our ﬁndings suggest limited clinical utility for routine use of intraoperative dextran during
CEA. (J Vasc Surg 2013;57:635-41.)Dextran is an organic polymer that was ﬁrst introduced Over the course of the past 65 years, dextran has been
into clinical practice in 1947 as a colloid plasma volume
expander.1 Since then, it has been noted to have multiple
antihemostatic functions including inhibition of platelet
adhesion and aggregation, interference with ﬁbrin poly-
merization, inhibition of erythrocyte aggregation, decrease
in blood viscosity, and enhancement of ﬁbrinolysis.2-7
Dextran has been commercially available as Dextran-40
and Dextran-70 based on a range of molecular weights of
constituent polymers.6,8 It has been approved by the
U.S. Food and Drug Administration for plasma volume
expansion (Dextran-40, Dextran-70) and prophylaxis
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://dx.doi.org/10.1016/j.jvs.2012.09.017prescribed in trauma, orthopedics, plastic and reconstruc-
tive surgery, and vascular surgery. It has been used as
a plasma volume expander in resuscitation of traumatic
injury,9 in venous thromboembolism prophylaxis after hip
surgery,10 to increase patency of anastamoses in micro-
vascular muscle transplantation,11 to decrease thrombosis
of disadvantaged infrainguinal grafts,12,13 and in arterial
thromboembolism prevention related to carotid endarter-
ectomy (CEA).14,15
Thromboembolic events are a signiﬁcant cause of peri-
operative stroke related to CEA,16 and vascular surgeons
have long sought to limit this risk through a variety of
technical and pharmaceutical adjuncts. Dextran has been
shown to reduce transcranial Doppler (TCD) embolic
signals after CEA,17-20 and its use has been shown to corre-
late with lower perioperative stroke rates.15,21 These data,
in conjunction with dextran’s known antithrombotic prop-
erties, have popularized its use in the setting of CEA
among some vascular surgeons.22
Despite these potential beneﬁts, dextran use has been
associated with allergic reactions, hemorrhage, hemodilu-
tion, pulmonary edema, and renal failure.6,8,23 Further-
more, its absolute beneﬁt in stroke prevention after CEA,
in the absence of TCD monitoring, remains uncertain,
and its utilization as an antithrombotic agent in other
settings has recently been questioned because of its associ-
ated risks.24 We sought to better understand inraoperative
dextran utilization in patients undergoing CEA and to635
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armamentarium of the modern vascular surgeon.
METHODS
Patients. We evaluated patients who underwent CEA
within the Vascular Study Group of New England (VSGNE),
which is a regional cooperative quality improvement initia-
tive developed in 2002 to prospectively study outcomes of
patients undergoing vascular surgery. The details of this
registry have been published previously25 and are avail-
able online at www.vsgne.org. The institutional review
board at Boston University School of Medicine and Public
Health has approved the use of the de-identiﬁed data for
this study.
Our patient cohort included consecutive patients who
underwent CEA to treat symptomatic and asymptomatic
carotid stenosis between 2003 and 2010 by surgeons prac-
ticing at both academic and community hospitals. Of the
7032 total procedures, we excluded those in patients
who had a history of ipsilateral CEA (159) and those that
were performed concurrently with coronary artery bypass
grafting (133). Patients on dialysis (36), those with a func-
tional transplant (12), those who underwent emergent
CEA (44), and those in whom age (three) or dextran use
(four) was not recorded were also excluded.
Outcome and variable deﬁnitions. In our analysis,
we reviewed patient demographics, clinical parameters,
and peri- and intraprocedural details. More than 100 clin-
ical and demographic variables were collected prospectively
on each procedure and entered into the VSGNE data-
base.25 Deﬁnitions of clinical parameters used in VSGNE
have been previously described.25 Index CEA procedures
were categorized into two groups based on whether or not
inraoperative dextran was administered. We assessed the
utilization of dextran among participating surgeons and
centers. Intraoperative dextran use was recorded in a binary
fashion according to whether or not it was used. Dose and
postoperative duration of administration were, however,
not recorded.
Our main outcome measures included postoperative
(30-day) death, ipsilateral stroke, all stroke (combination
of ipsilateral and contralateral stroke), or death, myocardial
infarction (MI), congestive heart failure (CHF), and
hospital length of stay (LOS). MI was deﬁned by new
electrocardiographic ST- and T-wave changes, troponin
elevation, or documentation by echocardiogram or other
imaging modality. CHF included new pulmonary edema
documented by chest radiograph and requiring treatment
or monitoring in the intensive care unit (www.vsgne.
org). Death and stroke rates at the 1-year follow-up were
also evaluated as descriptive analyses. No multivariable
analyses were performed for these outcomes.
Statistical analysis. Outcomes were compared on the
basis of intraoperative use of dextran during CEA. Patient
baseline demographics were compared between risk groups
using the c2 test and Fisher exact test (in cases when the
expected cell counts were low) for categorical variables
and the Student t-test for continuous variables. Thosevariables with P < .2, and those considered to be clinically
important were entered into multivariable regression
models. The following variables were considered as possible
confounders: gender, coronary artery disease, hypertension,
CHF, chronic obstructive pulmonary disease (COPD), pre-
operative use of aspirin and clopidogrel, symptomatic
status, urgency of the procedure, general anesthesia, endar-
terectomy technique, use of patch, and use of intraoperative
shunt. Logistic regression was used for MI, CHF, ipsilateral
stroke, and all stroke or death. Gamma regression was used
to analyze hospital LOS after early hospital deaths were
excluded. A backward elimination procedure with a .2 alpha
level to remain in the model was applied to construct a parsi-
monious model for each of the outcomes. Multivariable
analyses were performed in the entire crude study cohort.
Statistical analysis of the crude sample was the main
method used to compare outcomes between these
two groups. To assess the robustness of the results to
methodology, additional analyses were completed using
cohort-frequency group matching and stratiﬁed propensity
score matching to perform risk-adjusted comparisons
between these two groups.26,27 In cohort-frequency group
matching, each patient who received perioperative dextran
was matched with ﬁve untreated patients for the following
factors: coronary artery disease, COPD, preoperative clopi-
dogrel use, anesthesia type, use of patch, and use of intrao-
perative shunt. These matches were randomly selected from
the cohort of patients with the same values of the matching
variables. The ratio of 5 (no dextran) to 1 (dextran) in the
cohort match was based on the available pool of patients
and was chosen to maximize the effect of matching.28,29
The ﬁnal cohort for frequency matching included 1856
CEAs of which 333 CEAs received dextran and 1523
CEAs did not. We performed propensity score matching,
stratiﬁed by endarterectomy technique. Propensity scores
were calculated based on models for conventional and
eversion endarterectomy patients and included the same
factors that were used in cohort frequency matching
(above). These scores were then used to create two evenly
matched groups with 1/5 dextran/no dextran ratios for
comparison. The ﬁnal propensity score match cohort
included 2004 CEAs of which 334 received dextran and
1670 who did not.
Multivariable analyses were also performed adjusting
for surgeon and center effect using mixed effects models
and generalized estimating equations. Analyses were
performed using SAS 9.2 software (SAS Institute, Cary,
NC).
RESULTS
Our crude cohort comprised 6641 primary CEA
procedures performed on 6137 patients by 89 surgeons
at 17 centers in New England. Dextran was used intraoper-
atively in 334 (5%) procedures. The mean age of the
patients was 70 6 10 years, and 60% were male. Thirty
percent of patients were current smokers, 50% were prior
smokers, and most (90%) were treated with aspirin or
clopidogrel. Twenty-ﬁve percent of the CEA procedures
Fig 1. Relative utilization of dextran by surgeons within the
Vascular Study Group of Northern New England.
Table I. Demographic, clinical, and procedural variables of dextran-treated and untreated patients
Characteristic Overall (n ¼ 6641)a Dextran (n ¼ 334)a No dextran (n ¼ 6307)a P value
Demographics
Age, years 70 6 10 70 6 9 70 6 10 .62
Gender (male) 60% 65% 60% .03
Smoking (prior or current) 80% 79% 80% .68
Clinical parameters
Symptomatic 25% 25% 25% .94
Hypertension 87% 82% 88% .004
Coronary artery disease 33% 28% 33% .09
CHF 7% 9% 7% .22
COPD 23% 18% 23% .04
Diabetes 31% 31% 31% .98
Previous lower extremity bypass 6% 6% 6% .98
Aspirin 87% 85% 87% .53
Clopidogrel 16% 12% 17% .04
Aspirin or clopidogrel use 90% 87% 90% .14
Creatinine, mg/dL 1.1 6 0.5 1.2 6 0.4 1.1 6 0.5 .08
Hemoglobin, g/dL 13.6 6 3.7 13.3 6 1.7 13.6 6 3.8 .50
Procedural details
Type of surgery
Conventional endarterectomy 90% 81% 90% <.001
Eversion endarterectomy 10% 19% 10% —
Urgency, elective 90% 88% 90% .21
Anesthesia, general 88% 74% 89% <.001
Shunt use 47% 19% 49% <.001
Patch use 86% 61% 87% <.001
CHF, Congestive heart failure; COPD, chronic obstructive pulmonary disease.
aValues are expressed as percentages or the mean 6 standard deviation.
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were treated using conventional endarterectomy (90%),
underwent general anesthesia (88%), and were elective
(90%). In 47% of procedures, a shunt was used and 86%
of carotids were patched (Table I).
Patients who received dextran were more likely to be
male and less likely to have hypertension and COPD and
be treated with clopidogrel. Furthermore, they were less
likely to undergo a conventional versus an eversion endar-
terectomy, receive general anesthesia, be shunted, or be
repaired with a patch than patients who did not receive
dextran. There was no difference in symptomatic carotid
stenosis, urgency of surgery, or history of coronary artery
disease and CHF between groups (Table I).
Of the 89 surgeons performing CEA, 8% used dextran
routinely (>80% of cases), whereas 54% never used
dextran. Of the 38% of surgeons who used dextran selec-
tively, 62% used it in 1%-10% of cases and 38% used it in
11%-80% of cases (Fig 1). Dextran was used at 12 of 17
participating centers.
Bivariable analysis of the crude sample found no dif-
ferences in postoperative mortality, ipsilateral stroke, all
stroke, reoperation, and reoperation for bleeding between
dextran-treated and untreated patients. However, patients
treated with dextran had a higher incidence of postopera-
tive MI (2.4% dextran [D] vs 1.0% no dextran [ND];
P ¼ .029) and CHF (2.1% D vs 0.6% ND; P ¼ .005;
Fig 2, A). Patients treated with dextran had a longer
hospital LOS (2.6 6 3.7 days D vs 1.8 6 2.8 days ND;P < .001; Fig 2, B). There was no difference in 1-year
mortality (2.5% D vs 3.2% ND; P ¼ .724) and stroke
rate (0.4% D vs 0.8% ND; P ¼ .721) between the
dextran-treated and untreated patients, respectively.
On multivariable analysis of the crude cohort, use of
dextran was independently associated with increased risk
of postoperative MI (odds ratio [OR], 3.5; 95% conﬁdence
interval [CI], 1.6-7.6) and CHF (OR, 5.7; 95% CI,
2.4-13.9). There was no independent association between
dextran on reoperation, stroke, or death. Dextran use was
associated with a 50% increase in hospital LOS (means
Fig 2. Effect of dextran use on unadjusted patient outcomes (A) and length of stay (LOS) (B). The error bars extend
one standard error from the estimate in each direction. CHF, Congestive heart failure; MI, myocardial infarction.
Fig 3. Independent effect of dextran on clinical outcomes and
length of stay (LOS) based on multivariable analysis of the entire
carotid endarterectomy cohort. yOdds ratio (95% conﬁdence
interval [CI]) reported. zMeans ratio (95% CI) reported. CHF,
Congestive heart failure; MI, myocardial infarction.
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signiﬁcantly longer among patients receiving dextran,
even when patients who had postoperative MI and CHF
were excluded (means ratio, 1.5; 95% CI, 1.4-1.6).
We used frequency group matching and propensity
score matching techniques to allow for risk-adjusted
comparisons between the dextran-treated and untreated
cohorts. Table II reveals how selected characteristics of
COPD, use of general anesthesia, eversion endarterectomy,
and a shunt, which statistically differed between groups in
the entire (crude) sample, were successfully adjusted for
in the group-matched and propensity-matched compari-
sons. The complications of MI and CHF remained signiﬁ-
cant across these adjustments on bivariate analysis
(Table II). There was no signiﬁcant difference in stroke
and death rates between groups. Multivariable analyses of
the group-matched and propensity-matched samplesconﬁrmed the independent association of dextran with
the development of postoperative MI and CHF
(Table III).
We considered the effect of speciﬁc individual vascular
centers on the frequency of MI and CHF and found that
the rates of events were uniformly distributed across
centers. We then, formally, evaluated the inﬂuence of
surgeon and center effect on the relationship between
dextran and postoperative outcomes. When these effects
were included into multivariable analyses, the independent
effect of dextran on MI, CHF, and LOS remained signiﬁ-
cant (data not shown).
We also assessed the relationship of a history of CHF
with new postoperative CHF events. Of 43 postoperative
diagnoses of CHF made in the overall cohort, 25 occurred
in patients who lacked a history of CHF. Expressed
differently, 57% of patients who developed CHF in the
dextran-treated group did not have a prior history of
CHF. Likewise, 58% of patients who developed CHF in
the untreated cohort lacked a prior history of CHF (data
not shown).
DISCUSSION
Dextran is a macromolecule composed of repeating
glucose subunits that is synthesized by the action of the
bacterium Leuconostoc mesenteroides on sucrose.6 It has
been shown to reduce platelet deposition onto prosthetic
materials,30 and decreased platelet and ﬁbrin deposition
has been observed with its use in an animal model.31
Dextran’s antithrombotic effects have led to its use in
vascular surgery,12,13,15 and currently, certain vascular
surgeons employ dextran during CEA procedures in an
effort to diminish the risk of thromboembolic complica-
tions.18,21,22 We chose to assess the current utilization of
dextran in the setting of CEA amongU.S. vascular surgeons
and to assess both its efﬁcacy and risk proﬁle.
Table II. Bivariable analysis of patient characteristics and perioperative outcomes among crude, group-matched, and
propensity-matched cohorts
Crude cohort Group-matched cohort Propensity-matched cohort
Dextran
(n ¼ 334)
No dextran
(n ¼ 6397)
P
value
Dextran
(n ¼ 333)
No dextran
(n ¼ 1523)
P
value
Dextran
(n ¼ 334)
No dextran
(n ¼ 1670)
P
value
Characteristics
COPD 18% 23% .04 18% 17% .66 18% 17% .42
General anesthesia 74% 89% <.001 75% 79% .05 74% 77% .79
Eversion endarterectomy 19% 10% <.001 19% 25% .03 19% 19% .99
Shunt use 19% 49% <.001 19% 20% .63 19% 23% .09
Outcomes
Stroke or death 1.2% 1.0% .58 1.2% 0.6% .27 1.2% 0.7% .32
MI 2.4% 1.0% .03 2.4% 0.6% .01 2.4% 0.5% .003
CHF failure 2.1% 0.6% .01 2.1% 0.5% .01 2.1% 0.2% <.001
CHF, Congestive heart failure; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.
Table III. Multivariable analysis of crude, group-
matched, and propensity-matched cohorts
Dextran vs no dextran OR
Lower
CL
Upper
CL
P
value
Crude cohort
MI 3.5 1.6 7.6 .002
CHF 5.7 2.3 13.9 <.001
Ipsilateral stroke 0.5 0.1 2.2 .39
All stroke or death 1.0 0.4 2.5 .95
LOS 1.5 1.4 1.6 <.001
Group-matched cohort
MI 5.2 1.9 14.4 .002
CHF 5.9 1.9 18.5 .002
Ipsilateral stroke 0.8 0.2 3.3 .71
All stroke or death 1.2 0.4 3.2 .73
LOS 1.5 1.4 1.6 <.001
Propensity-matched cohort
MI 4.9 1.8 13.0 .002
CHF 8.4 1.9 37.0 .005
Ipsilateral stroke 0.8 0.2 3.8 .81
All stroke or death 1.3 0.5 3.6 .61
LOS 1.4 1.3 1.5 <.001
CHF, Congestive heart failure; CL, conﬁdence limit; LOS, length of stay;
MI, myocardial infarction; OR, odds ratio.
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used intraoperatively by a small proportion of vascular
surgeons during 5% of all CEAs. Of the surgeons who
prescribed it, 17% did so routinely (>80% of cases),
whereas 83% used it selectively (1%-80% of cases). These
practice patterns are similar to those in a recent survey of
399 European vascular surgeons that reported routine
use of dextran among 10% of responding surgeons.22
We found that dextran use was not associated with
a signiﬁcant decrease in the incidence of postoperative ipsi-
lateral stroke, all stroke, and stroke or death. These ﬁndings
were noted on bivariate analysis and conﬁrmed on multivar-
iate analyses. Furthermore, there was no signiﬁcant effect of
dextran on stroke rate at 1-year follow-up. The efﬁcacy of
dextran in CEA stems from evidence that postoperative
carotid thrombosis can be preceded by a phase ofasymptomatic microembolization, which can be detected
by TCD,17 and that patients who have >50 embolic signals
per hour are at an increased risk for stroke.32 Postoperative
administration of Dextran-40 has been shown to eliminate
postoperative TCD-diagnosed embolic signals in a pros-
pective study of 100 patients undergoing CEA.18 Dextran
infusion was as effective during 3 hours of TCD moni-
toring after CEA as for longer durations.19 Imple-
mentation of a protocol that included postoperative
TCD monitoring and dextran infusion to treat sustained
postoperative TCD-detected embolization has led to
a signiﬁcant decrease in postoperative stroke.15,21 Lastly,
preoperative dextran was noted to decrease the TCD-
detected emboli in a cohort of patients with symptomatic
carotid stenosis.20 Unfortunately, neither the use of TCD
in the setting of CEA, nor its dose or duration of admini-
stration, was recorded in the VSGNE registry. We believe
that most surgeons who used dextran intraoperatively did
so based on routine practice or some surgical or clinical
occurrence led to its selective use. Use of dextran with-
out routine TCD-based guidance may partially explain
its lack of efﬁcacy in our study.
The use of dextran in our series was associated with
a signiﬁcantly increased risk of MI and CHF. Increased
risk for these events was noted on our bivariate analysis,
and dextran was independently associated with increased
risk of MI and CHF on multivariate analysis. The corrob-
oration of these ﬁndings through adjustment using group
matching and propensity score-matching techniques sup-
ports the validation of the independent effect of dex-
tran on the development of CHF and MI after CEA
(Table III). Further, it is interesting to note that more
than half of patients who developed CHF did not have
a preoperative history of CHF.
CHF and MI may result from osmotic effects of
dextran causing volume expansion. CHF was observed in
5% of patients in one series,20 but in another study, there
were no reported cardiac complications associated with
dextran infusion after CEA.18 Dextran has been described
to have other complications such as bleeding and renal
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640 Farber et al March 2013failure, and this is one reason why patients on hemodialysis
were excluded from our cohort. Lastly, dextran is rarely
associated with allergic and anaphylactoid reactions,8 and
this is the reason why preinfusion of a low-molecular-
weight dextran (Dextran-1, molecular weight 1000;
Promit, Media AB Pharmaceuticals, Solna, Sweden) is rec-
ommended. In their study of dextran-related complications
after head and neck surgery, Disa et al24 reported that up to
29% of systemic complications, including CHF, MI, and
pulmonary edema, occurred after 48 hours of dextran infu-
sion. We do not have any information as to the incidence of
these complications or to the use of Dextran-1 in our
cohort of patients.
In our study, the use of dextran was independently
associated with increased hospital LOS. Increased LOS
was not a result of increased MI and CHF rates, as it
remained signiﬁcantly longer in the dextran-treated
patients even on exclusion of patients who had MI or
CHF. Furthermore, increased LOS among patients
receiving dextran was observed even after center effect
was formally adjusted for. The reasons for these ﬁndings
are not clear, and more precise determination of underlying
explanations regarding the differences in LOS in these
patients is beyond the scope of this study. Although
TCD-directed dextran therapy was noted to be cost-
effective in preventing carotid thrombosis in England,15
non-TCD-directed dextran use does not appear to be
cost-effective given the ﬁndings in our region.
There are important limitations to our ﬁndings. First,
ours is an observational study of a prospectively collected
database rather than a randomized trial. Although we
adjusted for differences between patients on the basis of
dextran use and did so using three different techniques,
there may still be confounders that were not detected.
Second, although we have made an assumption that
Dextran-40 was the most likely dextran used by surgeons
in this study, we cannot be certain that some did not use
other dextrans such as Dextran-70. Third, we do not
have information as to the exact dextran infusion rate,
duration of infusion, volume of infusion, and timing of
infusion. It is conceivable that cardiac complications in
patients receiving dextran may have been related to high
volumes or rates of dextran administration. Fourth, we
do not know why dextran infusion was used among the
38% of surgeons who used it selectively. Lastly, although
we adjusted for some surgeon factors such as surgical tech-
nique (conventional versus eversion CEA), other surgeon-
related factors may confound our ﬁndings.
We analyzed ﬁve outcomes that we felt to be very rele-
vant to the main question addressed in the article: Is the
use of dextran associated with cardiac complications after
carotid endarterectomy? We chose to report unadjusted
P values and included in the discussion a reference to
adjustment. As the P values for the association of the
main risk factors and outcomes are either below .01 or
>.1 and based on the fact that we have ﬁve outcome
measures, the results hold even when using a conservative
adjustment procedure such as Bonferroni. However, theoutcomes are clearly correlated, and so, we expect that
such a procedure is way too conservative.
Despite its limitations, the utility of the VSGNE data-
base has been validated through multiple studies.33,34 Its
strength lies in its large size, the comprehensive repository
of variables collected, and its regular adjudication process.
Our series represents the largest series of dextran use in
the setting of CEA and sheds light on effects and associated
complications of its use. Another strength of our study is
that we used multiple distinct adjustment strategies to
control for the differences between the dextran-treated
and untreated patients. These strategies support our ﬁnd-
ings that intraoperative use of dextran not based on
TCD-detected emboli in the setting of CEA is not associ-
ated with a decrease in perioperative stroke but is associ-
ated with increased CHF, MI, and LOS. Although
TCD-directed use of dextran in patients undergoing
CEA may have value, our ﬁndings support the conclusion
that intraoperative dextran should not be routinely used
in the context of CEA.
The authors acknowledge the assistance of Robert
Eberhardt, MD, with data analysis and interpretation, as
well as with critical revision of the article.
AUTHOR CONTRIBUTIONS
Conception and design: AF, TWT, JA, NH, PG, JC
Analysis and interpretation: AF, TWT, JA, PG, JC
Data collection: AF, TWT, DR, GD
Writing the article: AF, TWT
Critical revision of the article: AF, TWT, JA, NH, DR, GD,
PG, JC
Final approval of the article: AF, TWT, JA, NH, DR, GD,
PG, JC
Statistical analysis: DR, GD
Obtained funding: Not applicable
Overall responsibility: AF, TWT
REFERENCES
1. Paull J. Dextrans. Dev Biol Stand 1987;67:133-8.
2. Erdtmann M, Keller R, Baumann H. Photochemical immobilization of
heparin, dermatan sulphate, dextran sulphate, and endothelial cell
surface heparin sulphate onto cellulose membranes for the preparation
of athrombogenic and antithrombogenic polymers. Biomaterials
1994;15:1043-8.
3. Zeerleder S, Mauron T, Lammle B, Wuillemen WA. Effect of low
molecular weight dextran sulfate on coagulation and platelet function
tests. Thromb Res 2002;105:441-6.
4. Muzzafar TZ, Stalker AL, Bryce WA, Dhall DP, Smith G. Dextran and
ﬁbrin morphology. Nature 1972;238:288-90.
5. Barshtein G, Tamir I, Yedgar T. Red blood cell rouleaux formation in
dextran solution: dependence on polymer conformation. Eur Biophys J
1998;27:177-81.
6. Abir F, Barkhordarian S, Sumpio BE. Efﬁcacy of dextran solutions in
vascular surgery. Vasc Endovasc Surg 2004;38:483-91.
7. Jones CI, Payne DA, Hayes PD, Naylor AR, Bell PR, Thompson MM,
et al. The antithrombotic effect of Dextran-40 in man is due to
enhanced ﬁbrinolysis in vivo. J Vasc Surg 2008;48:715-22.
8. Zindermann CE, Landow L, Wise RP. Anaphylactoid reactions to
Dextran 40 and 70: reports to the United States Food and Drug
Administration, 1969 to 2004. J Vasc Surg 2006;43:1004-9.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 3 Farber et al 6419. Wade CE, Grady JJ, Kramer GC. Efﬁcacy of hypertonic saline dextran
ﬂuid resuscitation for patients with hypotension from penetrating
trauma. J Trauma 2003;54:S144-8.
10. Ljungstrom KG. Prophylaxis of postoperative thromboembolism with
Dextran-70: improvements of efﬁcacy and safety. Acta Chir Scand
1983;514(suppl):1-40.
11. Ridha H, Jallali N, Butler PE. The use of dextran post free tissue
transfer. J Plast Reconstr Aesthet Surg 2006;59:951-4.
12. Katz SG, Kohl RD. Does Dextran 40 improve the early patency of
autogenous infrainguinal bypass grafts? J Vasc Surg 1998;28:23-6.
13. Rutherford RB, Jones DN, Bergentz SE, Bergqvist D, Karmody AM,
Dardik H, et al. The efﬁcacy of Dextran-40 in preventing early post-
operative thrombosis following difﬁcult lower extremity bypass. J Vasc
Surg 1984;1:765-73.
14. Levi CR, Stork JL, Chambers BR, Abbott AL, Cameron HM,
Peeters A, et al. Dextran reduces embolic signals after carotid endar-
terectomy. Ann Neurol 2001;50:544-7.
15. Hayes PD, Lloyd AJ, Lennard N, Wolstenholme JL, London NJ,
Bell PR, et al. Transcranial Doppler-directed Dextran-40 therapy is
a cost-effective method of preventing carotid thrombosis after carotid
endarterectomy. Eur J Vasc Endovasc Surg 2000;19:56-61.
16. Riles TS, Imparato AM, Jacobowitz GR, Lamparello PJ, Giangola G,
Adelman MA, et al. The cause of perioperative stroke after carotid
endarterectomy. J Vasc Surg 1994;19:206-14.
17. Guant ME. Early diagnosis of postoperative carotid occlusion using
transcranial Doppler ultrasound. J Vasc Surg 1994;20:1004-5.
18. Lennard N, Smith J, Dumville J, Abbott R, Evans DH, London NJ,
et al. Prevention of postoperative thrombotic stroke after carotid
endarterectomy: the role of transcranial Doppler ultrasound. J Vasc
Surg 1997;26:579-84.
19. Lennard N, Smith JL, Hayes P, Evans DH, Abbott RJ, London NJ,
et al. Transcranial Doppler directed dextran therapy in the prevention
of carotid thrombosis: three hour monitoring is as effective as six hours.
Eur J Vasc Endovasc Surg 1999;17:301-5.
20. Lennard NS, Vijayasekar C, Tiivas C, Chan CW, Higman DJ,
Imray CH. Control of emboli in patients with recurrent or crescendo
transient ischaemic attacks using preoperative transcranial Doppler-
directed dextran therapy. Br J Surg 2003;90:166-70.
21. Naylor AR, Hayes PD, Allroggen H, Lennard N, Gaunt ME,
Thompson MM, et al. Reducing the risk of carotid surgery: a 7 year
audit of the role of monitoring and quality control assessment. J Vasc
Surg 2000;32:750-9.
22. Hamish M, Gohel MS, Shepherd A, Howes NJ, Davies AH. Variations
in the pharmacological management of patients treated with carotidendarterectomy: a survey of European vascular surgeons. Eur J Vasc
Endovasc Surg 2009;38:402-7.
23. Berg EM, Fasting S, Sellevold OFM. Serious complications with
dextran 70 despite hapten prophylaxis. Anaesthesia 1991;46:1033-5.
24. Disa JJ, Polvora VP, Pusic AL, Singh B, Cordeiro PG. Dextran-related
complications in head and neck microsurgery: do the beneﬁts outweigh
the risk? A prospective randomized analysis. Plast Reconstr Surg
2003;112:1534-9.
25. Cronenwett JL, Liksoky DS, Russell MT, Eldrup-Jorgensen J,
Stanley AC, Nolan M, for the Vascular Study Group of Northern New
England (VSGNNE). A regional registry for quality assurance and
improvement. J Vasc Surg 2007:1093-102.
26. D’Agostino RB. Propensity score methods for bias reduction in the
comparison of a treatment to a non-randomized control group. Statist
Med 1998;17:2265-81.
27. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research:
principles and quantitative methods. New York: Van Nostrand Rain-
hold; 1982.
28. Miettinen OS. Individual matching with multiple controls in the case of
all-or-none responses. Biometrics 1969;25:339-55.
29. Rubin DB. Matching to remove bias in observational studies.
Biometrics 1973;29:159-83.
30. Shoenfeld NA, Eldrup-Jorgensen J, Connolly R, Callow AD,
Valeri CR, Ramberg K, et al. The effect of low molecular weight
dextran on platelet deposition onto prosthetic materials. J Vasc Surg
1987;5:76-82.
31. Rothkopf DM, Chu B, Bern S, May JW Jr. The effect of dextran on
microvascular thrombosis in an experimental rabbit model. Plast
Reconstr Surg 1993;92:511-5.
32. Levi CR, O’Malley HM, Fell G, Roberts AK, Hoare MC, Royle JP,
et al. Transcranial Doppler detected cerebral microembolism following
carotid endarterectomy: high microembolic signal loads predict post-
operative cerebral ischemia. Brain 1997;120:621-9.
33. Stone DH, Nolan BW, Schanzer A, Goodney PP, Cambria RA,
Likosky DS, et al, for the Vascular Study Group of Northern New
England. Protamine reduces bleeding complications associated with
carotid endarterectomy without increasing the risk of stroke. J Vasc
Surg 2010;51:559-64.
34. Goodney PP, Likosky DS, Cronenwett JL. Factors associated with
stroke or death after carotid endarterectomy in northern New England.
J Vasc Surg 2008;48:1139-45.Submitted Jun 19, 2012; accepted Sep 18, 2012.
